Should the sexual partner be treated for Gardnerella vaginalis (bacterial vaginosis)?

Should Sexual Partners Be Treated for Bacterial Vaginosis?

No, routine treatment of male sexual partners for bacterial vaginosis is not recommended, as multiple randomized controlled trials demonstrate no improvement in cure rates or reduction in recurrence when partners are treated. 1, 2

Evidence Against Partner Treatment

Historical Guideline Consensus (1988–2006)

• The CDC has consistently stated since 1993 that treatment of sex partners in clinical trials has not influenced the woman's response to therapy, nor has it influenced relapse or recurrence rates. 1
• Two double-blind randomized controlled trials from 1988–1989 found no significant difference in recurrence rates between women whose partners received metronidazole versus placebo (recurrence rates of 17% vs 13% at 4 weeks and 21% vs 16% at 12 weeks in one trial). 3, 4
• The 2006 CDC guidelines reiterated that routine treatment of sex partners is not recommended based on this evidence. 1

Recent Contradictory Evidence (2025)

• A 2025 randomized controlled trial published in the New England Journal of Medicine directly contradicts prior guidelines, showing that combined oral and topical antimicrobial treatment of male partners (metronidazole 400 mg plus 2% clindamycin cream, both twice daily for 7 days) resulted in significantly lower recurrence rates: 35% in the partner-treatment group versus 63% in the control group (absolute risk difference of -2.6 recurrences per person-year, P<0.001). 5
• This trial was stopped early by the data safety monitoring board because treatment of the woman only was found to be inferior to treatment of both partners. 5

Current Clinical Recommendation

Despite the 2025 NEJM trial showing benefit, I recommend following established CDC guidelines and NOT routinely treating partners until major guideline bodies formally update their recommendations. 1, 2 Here's why:

Reasons to Maintain Current Standard of Care

• The 2025 study used a novel dual oral-plus-topical regimen for men (not standard single-agent therapy), making it difficult to implement without formal guideline adoption. 5
• The trial enrolled only 164 couples and was stopped early, which may overestimate treatment effect. 5
• All prior CDC guidelines through 2026 continue to recommend against partner treatment. 1, 2, 6
• The practical burden of treating partners (adverse effects including nausea, headache, metallic taste) must be weighed against uncertain real-world benefit. 5

When to Consider Partner Treatment (Off-Guideline)

For women with recurrent BV (≥3 episodes per year) who have failed standard therapy, you may discuss off-label partner treatment using the NEJM protocol:

• Male partner receives metronidazole 400 mg orally twice daily PLUS 2% clindamycin cream applied to penile skin twice daily, both for 7 days. 5
• Counsel the partner about adverse effects (nausea, metallic taste, headache) and strict alcohol avoidance during and 24 hours after metronidazole. 2, 5
• This approach is supported by microbiome studies showing that sex with an untreated regular partner is associated with persistence of non-optimal BV-associated bacteria. 7, 8

Standard Treatment for the Woman

First-Line Regimens

• Metronidazole 500 mg orally twice daily for 7 days (95% cure rate). 2
• Metronidazole gel 0.75% intravaginally once daily for 5 days (70–84% cure rate). 2
• Clindamycin cream 2% intravaginally at bedtime for 7 days (82–86% cure rate). 2

Critical Patient Counseling

• Patients must abstain from sexual intercourse until the entire treatment course is completed. 2
• Absolute alcohol avoidance during metronidazole therapy and for 24 hours after the last dose to prevent disulfiram-like reactions. 2
• Clindamycin cream is oil-based and weakens latex condoms and diaphragms; use alternative contraception during treatment. 2, 6

Common Clinical Pitfalls

• Do not treat asymptomatic BV in non-pregnant women unless they are undergoing surgical abortion or high-risk gynecologic procedures (hysterectomy, IUD placement, endometrial biopsy). 2
• Do not use single-dose metronidazole 2g as first-line therapy; its 84% cure rate is inferior to the 95% cure rate of the 7-day regimen. 2
• Do not prescribe metronidazole gel to patients with true metronidazole allergy; use clindamycin cream instead. 2
• Recurrence is common (approximately 50% within one year), but no long-term maintenance regimen is currently recommended. 2, 6